|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
5
|
|
gptkbp:bfsParent
|
gptkb:Ciba-Geigy
|
|
gptkbp:activities
|
phosphodiesterase type 5 inhibitor
|
|
gptkbp:approves
|
gptkb:1998
gptkb:FDA
|
|
gptkbp:brand
|
Viagra
Revatio
|
|
gptkbp:clinical_trial
|
erectile dysfunction studies
pulmonary arterial hypertension studies
|
|
gptkbp:contraindication
|
nitrates
severe cardiovascular disorders
|
|
gptkbp:developed_by
|
gptkb:Pfizer
|
|
gptkbp:dosage_form
|
100 mg
50 mg
25 mg
12.5 mg
|
|
gptkbp:duration
|
4 to 6 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:form
|
tablets
oral suspension
injectable form
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Sildenafil
|
|
gptkbp:ingredients
|
C22 H30 N6 O4 S
combination drugs
|
|
gptkbp:interacts_with
|
antihypertensives
protease inhibitors
alpha-blockers
other PD E5 inhibitors
|
|
gptkbp:invention
|
gptkb:2020
|
|
gptkbp:is_available_on
|
generic drug
|
|
gptkbp:is_used_for
|
erectile dysfunction
pulmonary arterial hypertension
|
|
gptkbp:manager
|
oral
|
|
gptkbp:marketed_as
|
gptkb:legislation
gptkb:Australia
gptkb:India
gptkb:United_States
gptkb:Native_American_tribe
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:premiered_on
|
30 to 60 minutes
|
|
gptkbp:research_areas
|
cardiovascular health
sexual health
|
|
gptkbp:safety_features
|
Category B
|
|
gptkbp:side_effect
|
headache
nasal congestion
flushing
visual disturbances
dyspepsia
|
|
gptkbp:type_of
|
171596-29-5
|